Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Keros Therapeutics, Inc. (KROS)

Keros Therapeutics Q3 Net Income of $14.2 Million vs. $7.3 Million Loss a Year Earlier

Positive Impact 3 of 5 earnings Written later

Keros Therapeutics reported net income of $14.2 million for the quarter ended September 30, 2026, compared with a net loss of $7.3 million in the same quarter of 2025. The increase was primarily due to $40.0 million of license revenue recognized under its Takeda license agreement. For the nine months, the company still posted a net loss of $38.3 million, and it said its cash will fund operations into the second half of 2028.

Key points

  • Q3 2026 total revenue was $40.0 million, up from $14.3 million in Q3 2025, driven by license revenue from Takeda.
  • Q3 2026 research and development expenses were $20.5 million and general and administrative expenses were $6.7 million.
  • Cash and cash equivalents were $259.5 million at September 30, 2026, down from $287.4 million at December 31, 2025.
  • Nine-month 2026 net loss was $38.3 million, compared with net income of $110.5 million in the first nine months of 2025.

The filing

CompanyKeros Therapeutics, Inc. (KROS)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:02 PM ET
Accession number0001664710-26-000065

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.